Minerval
Sourceunknownno stored text

CANTOS: Canakinumab reduces recurrent CV event rates in MI, inflammation

Author not recordedDate not recordedOriginal︎ ↗Archived copy

Claims1
ExaminationsNone
TextNot stored
VersionsOne known
CopiesNone recorded
CorrectionsNone recorded
Facts checked Nov 9, 2026
ReachNo copies recorded
StructureIn 1 claim's map0 sources downstream across 1 claim
EvidenceNot yet read
ReviewsNot reviewed

Examinations

None recorded. An examination is commissioned by a claim’s Steward for what its claim rests on; a review of the document for its own sake is asked for as a request bearing on it.

Text

No stored copy. Only the passages claims quote are recorded.

As quoted

Patients with a history of MI and an elevated high-sensitivity C-reactive protein level treated with canakinumab had a lower rate of recurrent CV events compared with placebo, according to results of the CANTOS trial presented at the European Society of Cardiology Congress.

In the CANTOS trial, canakinumab reduced recurrent cardiovascular events without lowering LDL cholesterolVerified

Not yet read by this claim’s Steward.

Lineage across 1 claim

Draws on · none recorded
This source
CANTOS: Canakinumab reduces recurrent CV event rates in MI, inflammation
in 1 claim's map
Drawn on by · none recorded

Record

Kind
unknown
Authors
Not recorded
Publisher
Not recorded
Published
Not recorded
DOI
None
Link
https://www.healio.com/news/cardiology/20170827/cantos-canakinumab-reduces-recurrent-cv-event-rates-in-mi-inflammation
Archived copy
https://web.archive.org/web/20240921150534/https://www.healio.com/news/cardiology/20170827/cantos-canakinumab-reduces-recurrent-cv-event-rates-in-mi-inflammation
Stored text
None; quoted passages only
Claims extracted
Not recorded
Versions
One known
Copies
None recorded
Corrections
None recorded
Facts checked
Nov 9, 2026

History 3

  1. Nov 11, 2026DividedSegmenter · Divided into 282 parts by its own structure
  2. Nov 11, 2026FactsFacts fetcher · Facts looked up
  3. Nov 11, 2026Entered the graphEntered the graph; copy stored
CANTOS: Canakinumab reduces recurrent CV event rates in MI, inflammation · Minerval